HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I.

Abstract
Oral delivery of toxin-negative derivatives of enterotoxigenic Escherichia coli (ETEC) that express colonization factor antigens (CFA) with deletions of the aroC, ompC, ompF, and toxin genes may be an effective approach to vaccination against ETEC-associated diarrhea. We describe the creation and characterization of an attenuated CFA/I-expressing ETEC vaccine candidate, ACAM2010, from a virulent isolate in which the heat-stable enterotoxin (ST) and CFA/I genes were closely linked and on the same virulence plasmid as the enteroaggregative E. coli heat-stable toxin (EAST1) gene. A new suicide vector (pJCB12) was constructed and used to delete the ST and EAST1 genes and to introduce defined deletion mutations into the aroC, ompC, and ompF chromosomal genes. A phase I trial, consisting of an open-label dose escalation phase in 18 adult outpatient volunteers followed by a placebo-controlled double-blind phase in an additional 31 volunteers, was conducted. The vaccine was administered in two formulations, fresh culture and frozen suspension. These were both well tolerated, with no evidence of significant adverse events related to vaccination. Immunoglobulin A (IgA) and IgG antibody-secreting cells specific for CFA/I were assayed by ELISPOT. Positive responses (greater than twofold increase) were seen in 27 of 37 (73%) subjects who received the highest dose level of vaccine (nominally 5 x 10(9) CFU). Twenty-nine of these volunteers were secreting culturable vaccine organisms at day 3 following vaccination; five were still positive on day 7, with a single isolation on day 13. This live attenuated bacterial vaccine is safe and immunogenic in healthy adult volunteers.
AuthorsArthur K Turner, Juliet C Beavis, Jonathan C Stephens, Judith Greenwood, Cornelia Gewert, Nicola Thomas, Alison Deary, Gabriella Casula, Alexandra Daley, Paul Kelly, Roger Randall, Michael J Darsley
JournalInfection and immunity (Infect Immun) Vol. 74 Issue 2 Pg. 1062-71 (Feb 2006) ISSN: 0019-9567 [Print] United States
PMID16428753 (Publication Type: Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Antibodies, Bacterial
  • Escherichia coli Proteins
  • Escherichia coli Vaccines
  • Immunoglobulin A
  • Immunoglobulin G
  • Vaccines, Attenuated
  • colonization factor antigens
  • Fimbriae Proteins
Topics
  • Adolescent
  • Adult
  • Antibodies, Bacterial (blood)
  • Child
  • Double-Blind Method
  • Escherichia coli (genetics, immunology, pathogenicity)
  • Escherichia coli Infections (prevention & control)
  • Escherichia coli Proteins (administration & dosage, adverse effects, genetics, immunology)
  • Escherichia coli Vaccines (administration & dosage, adverse effects, genetics, immunology)
  • Female
  • Fimbriae Proteins (administration & dosage, adverse effects, genetics, immunology)
  • Gene Deletion
  • Humans
  • Immunization
  • Immunoglobulin A (blood)
  • Immunoglobulin G (blood)
  • Male
  • Middle Aged
  • Plasmids
  • Treatment Outcome
  • Vaccines, Attenuated (administration & dosage, adverse effects, genetics, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: